Mohannad Abou Saleh, MD: Examining Follow-Up After Pancreatic Cyst Removal

Video

Experts recommend closer follow-up after the surgical removal of pancreatic cysts.

New research presented at the annual American College of Gastroenterology (ACG) 2020 conference recommend close follow-up and continued surveillance of pancreatic cysts following surgical excision.

A team of researchers from the Cleveland Clinic described the post-surgical course of pancreatic cyst patients, while evaluating the rates and predictors of recurrent cysts, high-risk, and malignant transformation over a 5 year review of existing data.

In the cohort, the investigators examined data from 104 patients who underwent surgical intervention for pancreatic cysts with 37 (37.4%) cases undergoing pancreaticoduodenectomy and 62 (62.6%) undergoing distal pancreatectomy.

In the study there were 63% IPMN (74.55% side-branch), 14% MCN, 8% serous cystadenoma, 6% neuroendocrine neoplasm, 6% pseudocyst and 3% solid-pseudopapillary neoplasm. For surgical pathology, 27% of patients had adenocarcinoma and 14% had high grade dysplasia.

At the one-year mark following surgery, 34.5% had recent cysts with 5.1% with high-risk transformation and 11.7% malignant transformation. By year 5, these rates increased to 64.8%, 13.7%, and 19%, respectively.

The overall mortality rate was 13.5%, with 5.8% related to pancreatic causes over the 5 year review period.

In an interview with HCPLive®, Mohannad Abou Saleh, MD, an internist with the Cleveland Clinic, explained how the study relates to existing gastroenterology guidelines and what he thinks the lasting impact of the study will be.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.